Safety and immunogenicity of the synthetic malaria vaccine SPf66 in a large field trial
| Autor: | Oscar Sierra, Fanny Guzman, M. Valero, Claudia L. Rocha, Fernando Alvarado, Francisco Nuñez, Juan Carlos Falla, Julio C. Calvo, Luis Angel Murillo, Nohora Zapata, David Cortés Saavedra, Ana Lucia Mora, Rocío Farfán, Alberto Molano, José Fernando Velásquez, Teódulo Quiñones, Luz Mary Salazar, Norella Ortega, Roberto Amador, Fabiola Espejo, Jaime Castro, Mauricio Rojas, Elsa Mora, Carlos Coronell, Jaiver E. Rosas, L. M. Franco, Alberto Moreno, Manuel E. Patarroyo, Mauricio Orozco |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Adult
Male Protozoan Vaccines medicine.medical_specialty Erythema Adolescent Blotting Western Molecular Sequence Data Plasmodium falciparum Protozoan Proteins Antibodies Protozoan Blood Pressure Enzyme-Linked Immunosorbent Assay Internal medicine medicine Immunology and Allergy Animals Humans Amino Acid Sequence Malaria Falciparum Child biology Malaria vaccine business.industry Immunogenicity Vaccination Antibody titer Infant medicine.disease biology.organism_classification Recombinant Proteins Infectious Diseases Immunization Child Preschool Immunoglobulin G Immunology Female medicine.symptom business Malaria |
| Zdroj: | The Journal of infectious diseases. 166(1) |
| ISSN: | 0022-1899 |
| Popis: | In the first field trial with synthetic malaria vaccine SPf66 in a large population naturally exposed to malaria, 9957 persons greater than 1 year old and residing on the Colombian Pacific coast received three doses of the vaccine. To evaluate vaccine safety, clinical observations were made 30 min and 48 h after each immunization. There were no adverse reactions in 95.7% of cases. In the 4.3% of cases with adverse reactions, local induration and erythema were the most frequent. In a randomly selected group of vaccinees, anti-SPf66 antibody titers were measured after the third dose: 93% of the vaccinees raised antibodies to SPf66. Among these, 55% had titers greater than 1:1600. These results demonstrate the safety and immunogenicity of the SPf66 vaccine in a large field trial. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|